



◆ KTRH26

<b>Clone ID</b>	SeV-Ff-iPSC-SCS_KTRH26_P9	<b>Product</b>	Human iPS cells
<b>Source</b>	Peripheral Blood, Human	<b>Race</b>	Caucasian
<b>Passage No.</b>	9	<b>Gender</b>	Female
<b>Lot No.</b>	Fit__04KTRH26-220527	<b>Manufacture Dates</b>	June 14 <sup>th</sup> , 2022
<b>Culture medium</b>	StemFit AK03N	<b>Substrate</b>	iMatrix-511MG
<b>Culture method</b>	Feeder-free <sup>(※1)</sup>	<b>Grade</b>	Clinical grade
<b>Reprogramming method</b>	Sendai-virus		
<b>Use and Provision of this cell stock</b>	Please visit our web site for details ; <a href="https://www.cira-foundation.or.jp/e/project/stock.html">https://www.cira-foundation.or.jp/e/project/stock.html</a>		

(※1) Reference; Nakagawa, *et. al.*, Nat Biotechnol. 2008 26(1):101-106

**Test Result**

Test	Method	Result
<b>Sterility</b>	Direct inoculation method	Negative
<b>Mycoplasma</b>	qPCR	Negative
<b>Endotoxin</b>	LAL	≤ 5 EU/mL
<b>Virus</b> (HBV, HCV, HIV, HTLV, Parvovirus B19)	qPCR	Negative
<b>HLA typing</b> (HLA-A, B, DR)	PCR-SBT	Consistent with the donor cells
<b>STR genotyping</b>	PCR	Consistent with the donor cells
<b>Morphology</b>	Microscope	Consistent with human ES cells
<b>Karyotype</b>	G-banding	46,XX[20]
<b>SeV remnants</b>	qPCR	Below the limit of quantification
<b>CNV<sup>(※2)</sup></b>	CNV analysis	No de novo CNVs (>1kbp) were found in CDS.
<b>SNV/Indel<sup>(※3)</sup></b>	WGS, SNP	No de novo non-synonymous SNVs/Indels were found in COSMIC Cancer Gene Census (ver.92) and Shibata list <sup>(※4)</sup> .
<b>Undifferentiated markers</b>	WGS	TRA-1-60(+); 98.7% SSEA4(+); 99.4% TRA-2-49(+); 99.6% OCT3/4(+); 99.9%
<b>Thawed postnatal cells</b>	Counting the number of the cells <sup>(※5)</sup>	2.21 × 10 <sup>5</sup> cells (Survival rate; 91.7%)
<b>Number of proliferating</b>	Counting the number of the	16.94 × 10 <sup>5</sup> cells (Number of seeded cells;

<b>cells after thawing</b>	cells after culturing for 6 days <sup>(※6, 7)</sup> .	0.65 × 10 <sup>5</sup> cells)
<b>Cardiac differentiation</b>	Flow cytometry	Troponin T(+); 60.5%


(※2) CNV; Copy Number Variation

(※3) SNV/Indel; Single nucleotide variants /Insertion Deletion

(※4) The PMDA Science Board “Current Perspective on Evaluation of Tumorigenicity of Cellular- and Tissue-based Products Derived from induced Pluripotent Stem Cells (iPSCs) and iPSCs as Their Starting Materials” (Cellular- and Tissue-based Products Subcommittee, 20 August 2013)

(※5) NucleoCounter NC-200

### ■ Image



Please contact us if you have any questions.

([iPS-request@cira-foundation.or.jp](mailto:iPS-request@cira-foundation.or.jp))